RENBP and hematocrit: The study identified core targets including MAPK1, IL6, AKT1, VEGFA, EGFR, and TP53, highlighting their critical roles in the therapeutic efficacy of UR-AP.The investigation brought to light several vital signaling pathways, notably the AGE-RAGE signaling pathway, Fluid shear stress and atherosclerosis, Lipid and atherosclerosis, PI3K-Akt signaling pathway, and Calcium signaling pathway, which are instrumental in the action of UR-AP against HT.